INOVIO PHARMACEUTICALS INC's ticker is INO and the CUSIP is 45773H201. A total of 174 filers reported holding INOVIO PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 0.29 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $35,172 | -30.4% | 90,416 | -20.1% | 0.00% | -100.0% |
| Q2 2023 | $50,538 | +43.6% | 113,188 | +401.8% | 0.00% | 0.0% |
| Q4 2022 | $35,189 | -59.6% | 22,557 | -54.9% | 0.00% | -66.7% |
| Q2 2022 | $87,000 | -9.4% | 50,060 | +87.1% | 0.00% | 0.0% |
| Q1 2022 | $96,000 | -39.6% | 26,756 | +55.8% | 0.00% | -66.7% |
| Q1 2021 | $159,000 | – | 17,170 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CAXTON ASSOCIATES LP | 784,679 | $643,437 | 0.10% |
| Green Alpha Advisors, LLC | 146,300 | $119,966 | 0.08% |
| Virtus ETF Advisers LLC | 54,106 | $44,367 | 0.02% |
| Cedar Brook Financial Partners, LLC | 104,881 | $86,002 | 0.02% |
| PROFUND ADVISORS LLC | 418,749 | $343,374 | 0.02% |
| Arlington Capital Management, Inc. | 27,735 | $22,743 | 0.02% |
| Hennion & Walsh Asset Management, Inc. | 382,158 | $313 | 0.02% |
| Rafferty Asset Management, LLC | 2,647,927 | $2,171,300 | 0.02% |
| Brainard Capital Management LLC | 16,666 | $13,666 | 0.01% |
| Beck Bode, LLC | 41,218 | $33,799 | 0.01% |